Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2020-05-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
独立董事关于第一届董事会第十一次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various proposals to be discussed at the company's board meeting, including profit distribution, audit firm reappointment, director and senior management remuneration, accounting policy changes, and use of funds. It references the 2019 fiscal year and 2020 proposals, indicating it is related to governance and board-level decisions. The content is not a full financial report, audit report, or earnings release but rather opinions on board meeting agenda items. This fits the category of Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management matters. The document length is under 5,000 characters and contains detailed independent opinions on board proposals, not just an announcement or a report publication notice, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2020-05-19 Chinese
董事会审计委员会2019年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board Audit Committee 2019 Annual Performance Report" of Chengdu Lead Drug Development Co., Ltd. It details the audit committee's activities, meetings, evaluations of external and internal audits, review of financial reports, and internal control guidance for the year 2019. It is a report on the audit committee's duties and performance rather than a standalone audit opinion or a full annual report. The document length is 1913 characters, which is relatively short and focused on the audit committee's work rather than full financial statements. This fits the definition of an Audit Report / Information (AR), which includes audit reports and related information excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2019
2020-05-19 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2019 Annual General Meeting (AGM) of Chengdu Lead Drug Development Co., Ltd. It includes details about the meeting date, voting methods, agenda items to be discussed and voted on, and instructions for shareholders to attend and vote. The document does not contain actual financial statements or detailed financial analysis but rather serves as an announcement and invitation to the AGM. The document length is 4227 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-05-19 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司使用部分超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a financial institution (China International Capital Corporation) regarding the use of part of the company's over-raised funds to permanently supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the fundraising amount, usage plans, and approvals by the board and supervisory committee. The document is not a full financial report but rather a regulatory compliance and usage verification statement related to capital use. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it concerns the use of raised capital and compliance with fundraising regulations.
2020-05-19 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Chengdu Lead Drug Development Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the amount, types of financial products, investment purpose, risk control measures, and approvals by the board and supervisory committee. The document references regulatory guidelines on the management and use of raised funds and includes independent director opinions and sponsor verification. It is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about the company's capital management activities related to raised funds, specifically cash management of idle funds. This fits the category of Capital/Financing Update (CAP) as it updates on the company's use of capital raised through fundraising activities and its management of those funds.
2020-05-19 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 成都先导药物开发股份有限公司 (HitGen Inc.), covering company organization, shareholder rights, board structure, share issuance, share transfer, and governance rules. It references Chinese company law, securities law, and stock exchange listing rules. The content is about the internal governance framework, shareholder meetings, board responsibilities, share capital, and related corporate governance matters. There is no financial data, earnings information, audit results, or legal proceedings. It is not a report of financial results or an announcement of voting results. The document is a governance document detailing the company's internal rules and governance practices, fitting the Governance Information (CGR) category.
2020-05-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.